Literature DB >> 12470614

Adjuvanticity of an IL-12 fusion protein expressed by recombinant deltaG-vesicular stomatitis virus.

Sheri D Klas1, Clinton S Robison, Michael A Whitt, Mark A Miller.   

Abstract

The remarkable immunomodulatory and adjuvant properties of rIL-12 have been well described. Many early studies documenting the adjuvanticity of IL-12 were performed using the murine model of Listeria monocytogenes infection. In this report, we describe the construction of an attenuated recombinant vesicular stomatitis virus (VSV-deltaG) that encodes a single-chain IL-12 fusion protein (IL-12F), and the use of this virus as an expression vector to produce large quantities of IL-12F. VSV-expressed IL-12F (vIL-12F) was then co-administered to mice along with a poorly immunogenic listerial antigen preparation as a vaccine regimen and the resulting immune responses were monitored. The vIL-12F was found to have adjuvant properties similar to those observed for rIL-12. Co-administration of vIL-12F and listerial antigen elicited powerful cell-mediated immune responses that conferred long-lived protective listerial immunity. These studies demonstrated that VSVdeltaG-IL12F-infected cells secrete bioactive single-chain IL-12, and laid the foundation for studies using VSVdeltaG-IL12F as a vector for delivery of IL-12F in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470614     DOI: 10.1016/s0008-8749(02)00575-0

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines.

Authors:  Michael A Whitt
Journal:  J Virol Methods       Date:  2010-08-13       Impact factor: 2.014

2.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

Review 3.  Recombinant vaccines against the mononegaviruses--what we have learned from animal disease controls.

Authors:  Hiroki Sato; Misako Yoneda; Tomoyuki Honda; Chieko Kai
Journal:  Virus Res       Date:  2011-10-05       Impact factor: 3.303

Review 4.  Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.

Authors:  Hong-My Nguyen; Kirsten Guz-Montgomery; Dipongkor Saha
Journal:  Cells       Date:  2020-02-10       Impact factor: 6.600

Review 5.  Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.

Authors:  David K Clarke; David Cooper; Michael A Egan; R Michael Hendry; Christopher L Parks; Stephen A Udem
Journal:  Springer Semin Immunopathol       Date:  2006-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.